A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies
Open Access
- 30 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 115 (5) , 586-596
Abstract
Background: The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is used to assess symptomatic adverse events in oncology trials. Currently, no standard for PRO-CTCAE analysis exists.Methods: Key methods of descriptive analysis and longitudinal modeling using PRO-CTCAE data from an oncology clinical trial, DRiving Excellence in Approaches to Multiple Myeloma-2 (DREAMM-2), a phase II trial of belantamab mafodotin in multiple myeloma (NCT03525678), were explored. Descriptive methods included maximum postbaseline ratings, mean change over time, ratings above a predefined cutoff, line graphs, and stacked bar charts to illustrate patient-reported adverse events at one timepoint or dynamics over time. Analysis methods involving modeling over time included toxicity over time (ToxT) (repeated measurement model, time-to-event, area under the curve analyses), generalized estimating equations (GEE), and ordinal log-linear models (OLLMs).Results: Visualizations of PRO-CTCAE data highlighted different aspects of the data. Selection of the appropriate visualization will depend on the audience and message to be conveyed. Consistent results were obtained by all modeling approaches; no difference was found between dose groups of the DREAMM-2 study in any PRO-CTCAE item by the ToxT approach or the more sophisticated GEE and OLLM methods. Interpretation of GEE results was the most challenging. OLLM supported the interval nature of the PRO-CTCAE response scale in the DREAMM-2 study. All modeling approaches account for multiple testing (driven by the number of items).Conclusions: Descriptive analyses and longitudinal modeling approaches are complementary approaches to presenting PRO-CTCAE data. In modeling, the ToxT approach may be a good compromise compared with more sophisticated analyses.Keywords
Funding Information
- GSK
This publication has 30 references indexed in Scilit:
- Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: What makes a pro picture worth a thousand words?Patient Education and Counseling, 2016
- Communicating patient-reported outcome scores using graphic formats: results from a mixed-methods evaluationQuality of Life Research, 2015
- Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JNCI: Journal of the National Cancer Institute, 2014
- Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaBlood, 2014
- Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: Part of the MORECare research method guidance on statistical issuesPalliative Medicine, 2013
- Analysing randomised controlled trials with missing data: Choice of approach affects conclusionsContemporary Clinical Trials, 2012
- Investigating the missing data mechanism in quality of life outcomes: a comparison of approachesHealth and Quality of Life Outcomes, 2009
- Simple imputation methods were inadequate for missing not at random (MNAR) quality of life dataHealth and Quality of Life Outcomes, 2008
- Marginal Regression Models for Clustered Ordinal MeasurementsJournal of the American Statistical Association, 1996
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986